Intensity Therapeutics (INTS) announced the resumption of its Phase 2 INVINCBLE-4 trial for INT230-6 in triple-negative breast cancer. The update is a positive clinical milestone, though no efficacy or safety results were provided, limiting near-term visibility on outcomes.
Intensity Therapeutics (INTS) announced the resumption of its Phase 2 INVINCBLE-4 trial for INT230-6 in triple-negative breast cancer. The update is a positive clinical milestone, though no efficacy or safety results were provided, limiting near-term visibility on outcomes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
